Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NMAD with free AI briefings, catalyst countdowns, and dilution alerts.

NMAD · NOMAD POWER SOLUTIONS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar. Closed at $2.80, 29% below $3.93, its close on the day of its Sep 30 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$12.7M Cash on Hand
22.1mo Cash Runway
Follow NMAD by email Get an email when NMAD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NMAD, unsubscribe in one click. Privacy

📣 What NMAD Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

NMAD holds $12.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.7M/quarter from operations, an estimated runway of 22.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NMAD files for a raise →

👥 Who Owns NMAD

Insiders 13.3% Other 5%+ holders 33.8% Institutions (25 holders) 12.9% Public and other holders 40%
HolderTypeShares% of sharesAs of
Geordan Garrett Pursglove
Resigned as CEO & Chairman
Insider 2,122,687 11.52% 2026-11-09
Geordan Pursglove 5%+ holder (13G) 2,122,687 11.52% 2026-11-09
North York Ltd 5%+ holder (13G) 1,838,273 9.98% 2026-09-03
Beneth Capital LLC 5%+ holder (13G) 1,494,641 8.11% 2026-11-06
Strategic EP, LLC 5%+ holder (13G) 774,902 4.21% 2026-06-04
Vanguard Capital Management Institution (13G, 5%+) 622,756 3.38% 2026-06-30
Peter Stazzone
Chief Financial Officer
Insider 100,000 0.54% 2026-07-01
Jason David Sawyer
Director
Insider 65,000 0.35% 2026-07-01
Lourdes Felix
Director
Insider 55,000 0.30% 2026-07-01
Guy Warren Primus
Director
Insider 40,000 0.22% 2026-07-01
Michael Andrew Holloway
Director
Insider 40,000 0.22% 2026-07-01
Stuart D Porter
Director
Insider 25,000 0.14% 2026-05-29

Share count 18,419,632 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NMAD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NMAD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.